- Tumors1000+
- Cancer853
- Pathology709
- Pathologic Processes690
- Immune System Diseases538
Any
<10 miles
<30 miles
<50 miles
<70 miles
Filter Results
Condition
- Tumors1000+
- Cancer853
- Pathology709
- Pathologic Processes690
- Immune System Diseases538
Where are you looking?
How far are you willing to travel?Any
How old are you?
Trial Status
Recruiting statusPlacebo
Recruiting
Waitlist Available
Administration Type
Trial Phase
Biomarkers
Stage of Disease
- HER2 negative
- PD-L1 positive
- ER positive
- HER2 positive
- PD-L1 negative
- PR positive
- ER negative
- PR negative
- EGFR positive
- EGFR negative
- ALK negative
- BRAF positive
- BRCA1 positive
- KRAS positive
- BRCA2 positive
- ALK positive
- p16 positive
- CD20 positive
- ROS1 negative
- BRAF negative
- MYC positive
- PIK3CA positive
- MET positive
- ROS1 positive
- CD19 positive
- HLA positive
- RET positive
- p16 negative
- HLA-A positive
- HR positive
- IDH positive
- TP53 positive
- BCL2 positive
- BCL6 positive
- HBsAg positive
- HLA negative
- PALB2 positive
- BCR-ABL1 positive
- BRCA positive
- CCND1 positive
- Ex19del positive
- IDH negative
- L858R positive
- MET negative
- Philadelphia chromosome positive
- RET negative
- TP53 negative
- Anti-dsDNA positive
- BRCA1 negative
- HPV negative
- HPV positive
- PTEN positive
- RAS positive
- RB1 positive
- TTR positive
- ANA positive
- ATM positive
- BRCA2 negative
- CD30 positive
- FGFR2 positive
- HLA-A negative
- MMR positive
- NTRK negative
- NTRK positive
- PTEN negative
- RB1 negative
- T790M positive
- TROP2 negative
- TROP2 positive
- ctDNA positive
- dMMR positive
- t(11;14) positive
- APP positive
- C5 positive
- CD19CAR positive
- CD5 positive
- CFTR positive
- COL7A1 positive
- EBV positive
- FGFR3 positive
- FLT3 negative
- FLT3 positive
- FMR1 positive
- H3 K27M positive
- HBB positive
- HbSS positive
- JAK2 positive
- KRAS negative
- MDM2 positive
- NF1 positive
- NF2 positive
- NRAS negative
- NRAS positive
- PD-1 positive
- PSEN1 positive
- PSEN2 positive
- Philadelphia chromosome negative
- RF positive
- SMN1 positive
- SPINK5 positive
- p53 positive
- β-thalassemia positive
- 11q negative
- 11q positive
- 19q negative
- 1p negative
- ABCA4 positive
- AKT positive
- ALPL positive
- Anti-Smith positive
- ApoE ε4 positive
- Aβ1-42 positive
- CCND2 positive
- CCND3 positive
- CCNE1 positive
- CD23 positive
- CD30 negative
- CDK4 positive
- CLDN18.2 positive
- COL1A1 positive
- COL1A2 positive
- DICER1 positive
- DMD positive
- EPCAM positive
- ER or PR positive
- ER/PR positive
- EZH2 positive
- FGFR positive
- FKRP positive
- FOXO1 fusion negative
- FVIII positive
- G719X positive
- GLA positive
- HPV16 positive
- HRD positive
- HbE positive
- IAA positive
- IGHV negative
- IGHV positive
- KIT positive
- L861Q positive
- MGMT negative
- MLH1 positive
- MMR negative
- MSH2 positive
- MSH6 positive
- MSI-H negative
- MSI-H positive
- MSS positive
- MYC negative
- NTRK1 positive
- PD-1 negative
- PIK3CA negative
- PIK3CD positive
- PIK3R1 positive
- PKLR positive
- PMM2 positive
- PMS2 positive
- PTCH1 positive
- PiZZ positive
- RAS negative
- S768I positive
- TMB positive
- TTR negative
- ZnT8 positive
- anti-AChR positive
- anti-MuSK positive
- anti-Ro autoantibodies positive
- anti-Ro/SSA positive
- anti-Sm positive
- dMMR negative
- del(17p) negative
- del(17p) positive
- other sickle cell syndrome variants positive
- +8 positive
- \-13 negative
- \-13 positive
- \-13/del(13q) positive
- \-17/add(17p) or del(17p) positive
- \-17/add(17p) positive
- \-5q negative
- \-5q positive
- \-7 positive
- \-7/del(7q) positive
- 11q aberration positive
- 11q del negative
- 11q23 abnormalities positive
- 12 negative
- 12 positive
- 13q del negative
- 13q negative
- 13q positive
- 16p11.2 deletion positive
- 17p deletion positive
- 17p negative
- 17p positive
- 17p13 deletion negative
- 19q positive
- 1p positive
- 1p/19q co-deletion positive
- Gleason Score 10
- Gleason Score 6
- Gleason Score 7
- Gleason Score 8
- Gleason Score 9
- Grade 1
- Grade 2
- Grade 3
- Grade 4
- Stage IV
- Stage III
- Stage II
- Stage I
- 1927nm Fractional Thulium Laser Treatment
- 68Ga-DOTATATE PET/CT Scan
- Acyclovir
- Adjuvant Therapy (except reconstruction)
- Allogeneic Stem Cell Transplant
- Anti-HER2 Therapy
- Anti-Seizure Medications (up to 2 types)
- Any Number of Prior Systemic Therapy Lines for Locally Advanced Inoperable Tumor
- Any Number of Prior Systemic Therapy Lines for Metastatic Disease
- Any Treatment for Pancreatic Cancer
Trial Status
Recruiting statusPlacebo
Recruiting
Waitlist Available
Administration Type
Trial Phase
Biomarkers
Stage of Disease
3790 trials
Kingman, KS (<20 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing a 4-drug combo vs. a 3-drug combo to see if the former is more effective in shrinking cancer or preventing its return.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Kingman, KS (<20 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing if vitamin D3 along with regular cancer drugs and another drug that helps the immune system can better treat colorectal cancer that has spread. Vitamin D3 may help the body use essential minerals, making the cancer drugs more effective. Vitamin D3 has been shown to slow down cancer cell growth and help them mature, and it has been effective in reducing intestinal tumors in animal studies.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Kingman, KS (<20 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is comparing radiation therapy alone to radiation therapy with lymph node dissection in treating breast cancer patients who have already had chemotherapy and surgery.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Kingman, KS (<20 mi)
Waitlist
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial will test a combination of drugs to see if they are effective in reducing the chance of cancer recurrence or developing new cancers.
Efficacy & Safety Awards
Pivotal Trial
Kingman, KS (<20 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing a new drug called adagrasib against an existing chemotherapy drug, docetaxel. It focuses on patients with advanced lung cancer who have a specific genetic mutation (KRAS G12C) and have already had treatment. The new drug aims to block this mutation in cancer cells to stop their growth.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Kingman, KS (<20 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial studies how well nivolumab works in treating patients with non-small cell lung cancer. Nivolumab is an immunotherapy drug that helps the immune system attack cancer cells. The goal is to see if it can prevent the cancer from coming back. Nivolumab has shown efficacy in treating various malignancies, including non-small cell lung cancer.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Kingman, KS (<20 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is studying giving chemotherapy with or without trastuzumab after surgery to see how well they work in treating women with invasive breast cancer.
Efficacy & Safety Awards
Pivotal Trial
No Placebo-Only Group
Kingman, KS (<20 mi)
Waitlist
Phase 33 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial compares ipilimumab to interferon alfa-2b to see which is more effective in treating patients with high-risk stage III-IV melanoma.
Efficacy & Safety Awards
All Individual Drugs Already Approved
No Placebo-Only Group
Pivotal Trial
Kingman, KS (<20 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing 4 different hormone therapies with or without chemotherapy to see which is most effective in treating patients with invasive breast cancer.
Efficacy & Safety Awards
Pivotal Trial
No Placebo-Only Group
Get notified when new DCIS trials are postedWe'll send you an email whenever new trials are posted
Kingman, KS (<20 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial will study whether radiation therapy is more effective with or without trastuzumab in treating ductal carcinoma in situ.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Kingman, KS (<20 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing different radiation therapy regimens to see which is more effective in treating patients with limited-stage small cell lung cancer when given together with chemotherapy.
Efficacy & Safety Awards
Pivotal Trial
No Placebo-Only Group
Kingman, KS (<20 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing chemotherapy with or without bevacizumab to see how well it works in treating patients with head and neck squamous cell carcinoma that has come back or spread to other parts of the body.
Efficacy & Safety Awards
Pivotal Trial
No Placebo-Only Group
Kingman, KS (<20 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is comparing two treatments for neuroendocrine tumors - octreotide acetate with either recombinant interferon alfa-2b or bevacizumab. The goal is to see if octreotide acetate with recombinant interferon alfa-2b is more effective than with bevacizumab.
Efficacy & Safety Awards
Pivotal Trial
No Placebo-Only Group
Kingman, KS (<20 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is studying carboplatin, paclitaxel, and gemcitabine hydrochloride given together with or without bevacizumab after surgery to treat patients with ovarian, epithelial, primary peritoneal, or fallopian tube cancer.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Kingman, KS (<20 mi)
Waitlist
Phase 21 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing two different sets of cancer drugs to see which works better for patients with advanced neuroendocrine carcinoma that has spread or cannot be removed by surgery. The drugs aim to stop cancer from growing and spreading by attacking the cancer cells in different ways. One of the drugs being tested is used for treating advanced neuroendocrine tumors.
Efficacy & Safety Awards
No Placebo-Only Group
Kingman, KS (<20 mi)
Waitlist
Phase 1 & 2
0 Criteria Met
Eligibility Criteria
SummaryThis trial is studying the side effects and best dose of veliparib when given with radiation therapy, carboplatin, and paclitaxel to see how well it works in treating patients with stage III non-small cell lung cancer.
Kingman, KS (<20 mi)
Waitlist
Phase 1 & 21 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is studying the side effects and best dose of vorinostat when given with rituximab and chemotherapy to treat patients with newly diagnosed stage II-IV diffuse large B-cell lymphoma.
Efficacy & Safety Awards
No Placebo-Only Group
Kingman, KS (<20 mi)
Waitlist
Phase 21 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is studying the effects of a drug on patients with stage IV melanoma. The drug may stop the growth of tumor cells.
Efficacy & Safety Awards
No Placebo-Only Group
Get notified when new Breast Cancer trials are postedWe'll send you an email whenever new trials are posted
Kingman, KS (<20 mi)
Waitlist
Phase 21 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing paclitaxel with or without carboplatin and/or bevacizumab followed by doxorubicin and cyclophosphamide to see if it is effective in treating patients with breast cancer.
Efficacy & Safety Awards
No Placebo-Only Group
Kingman, KS (<20 mi)
Waitlist
Phase 21 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is studying side effects and efficacy of combine chemo w/ or w/o donor stem cell transplant for treating patients w/ acute lymphoblastic leukemia.
Efficacy & Safety Awards
No Placebo-Only Group
1
2
3
…50